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Abstract
Background
Smoking is a risk factor for tuberculosis (TB) infection and disease progression. Tobacco
smoking increases susceptibility to TB in a variety of ways, one of which is due to a reduction
of the IFN-γ response. Consequently, an impaired immune response could affect perfor-
mance of IFN-γ Release Assays (IGRAs).
Objective
In the present study, we assess the impact of direct tobacco smoking on radiological mani-
festations, sputum conversion and immune response to Mycobacterium tuberculosis, ana-
lyzing IFN-γ secretion by IGRAs.
Methods
A total of 525 participants were studied: (i) 175 active pulmonary TB patients and (ii) 350
individuals coming from contact tracing studies, 41 of whom were secondary TB cases. Clin-
ical, radiological and microbiological data were collected. T-SPOT.TB and QFN-G-IT were
processed according manufacturer’s instructions.
Results
In smoking patients with active TB, QFN-G-IT (34.4%) and T-SPOT.TB (19.5%) had high
frequencies of negative results. In addition, by means of an unconditional logistic regression,
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smoking was a main factor associated with IGRAs’ false-negative results (aOR: 3.35; 95%
CI:1.47–7.61; p<0.05). Smoking patients with active TB presented a high probability of hav-
ing cavitary lesions (aOR: 1.88; 95%CI:1.02–3.46;p<0.05). Mean culture negativization
(months) ± standard deviation (SD) was higher in smokers than in non-smokers (2.47±1.3
versus 1.69±1.4). Latent TB infection (LTBI) was favored in smoking contacts, being a risk
factor associated with infection (aOR: 11.57; 95%CI:5.97–22.41; p<0.00005). The IFN-γ
response was significantly higher in non-smokers than in smokers. Smoking quantity and
IFN-γ response analyzed by IGRAs were dose-dependent related.
Conclusions
Smoking had a negative effect on radiological manifestations, delaying time of sputum con-
version. Our data establish a link between tobacco smoking and TB due to a weakened IFN-
γ response caused by direct tobacco smoke.
Introduction
Tobacco smoking and tuberculosis (TB) remain as two serious global health threats. The
World Health Organization has stated that tobacco smoking results in approximately 6 million
deaths annually, and that diseases associated with smoking claim more lives than HIV, malaria
and TB together. In addition, TB killed 1.4 million people in 2015 [1, 2]. Currently, the associa-
tion between tobacco and TB has been underestimated because available studies have not con-
clusively provided a confirmatory link. However, recent investigations suggest that tobacco
smoking has a negative impact on TB outcome, resulting in delay in culture conversion during
therapy and frequently requiring treatment extension [3–9].
Several studies indicate that active and passive tobacco smoke exposure are risk factors for
latent tuberculosis infection (LTBI) and active TB progression. In addition, smoking has been
associated with cavitary lesions, bacillary load, smear conversion delay, and high risk of reacti-
vation and death during or after treatment. Of note, the relative risk of TB reactivation in
smokers is comparable with respect to the risk observed in end-stage renal disease patients or
individuals under anti-Tumour Necrosis Factor (TNF)-alpha (α) therapy [3–5, 10, 11].
T-cells producing Interferon (IFN)-gamma (γ) have a key role in the protective immunity
against Mycobacterium tuberculosis. IFN-γ Release Assays (IGRAs), introduced a decade ago,
are based on the detection of IFN-γ secreted by sensitized T-cells in peripheral blood after
stimulation with specific M. tuberculosis antigens. The two current assays based on this tech-
nology, approved by U.S. Food and Drug Administration (FDA) and European Commission
(EC) are QuantiFERON-TB Gold (QFN-G-IT, QIAGEN, Dusseldorf, Germany) and T-SPOT.
TB (Oxford Immunotec, Abingdon, UK). Both assays are useful approaches for LTBI diagnosis
because the specific antigens used in both technologies avoid cross-reaction with BCG-vaccine
and most of non-tuberculous mycobacteria (NTM) [12–15].
The effect of tobacco smoking on the immune system is not completely understood. It has
been demonstrated using murine models infected with M. tuberculosis that tobacco smoke
increases susceptibility to TB as a result of diminished recruitment of IFN-γ producing T-cells
to the lungs and spleens [16–18]. According to these studies, clinical performance of IGRAs,
based on IFN-γ secreting T-cells detection, could be affected by the impaired immune
response as a consequence tobacco smoke exposure. Consequently, their use in such kind of
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population may help clinicians to understand the immune status of the patient and to link it
with tobacco smoke.
The present study investigates the immune response against M. tuberculosis studied by
IGRAs, in smoking and non-smoking patients with active TB and LTBI-exposed contacts, as
well as the impact of smoking on radiological manifestations and microbiological evolution in
TB patients.
Materials and methods
Study design and sample collection
This is a prospective and cross-sectional study. Patients were recruited from June 2013 to May
2014. Data on demographic and clinical parameters were obtained through a questionnaire
during control routine consultation or/and at the moment of the inclusion. Active TB patients
and individuals coming from contact tracing studies were included. Patients were recruited in
Serveis Clı´nics [specialized center on Direct Observed Therapy (DOT) located in Barcelona]
and in the Unitat de Tuberculosi Vall d’Hebron-Drassanes (Hospital Universitari Vall
d’Hebron, Barcelona). A respiratory sample was obtained in all active pulmonary TB patients
for the diagnosis and control of the disease.
A total of 11mL of blood was drawn for performing the two IGRAs in all study participants.
Blood was collected at the same time of TST testing. Blood for T-SPOT.TB and QFN-G-IT was
directly sent to Institut d’Investigacio´ Germans Trias i Pujol for assay testing. This study has
been approved by the Ethical Committee of the Institut d’Investigacio´ en Atencio´ Primària
(IDIAP) Jordi Gol in Barcelona. Informed consent was obtained for patient participation. All
the data regarding patient identification and information was handled in a confidential man-
ner and in accordance with the Spanish Law 15/1999 on the Protection of Personal Character
Data.
Study population
The participants in this study included active pulmonary TB patients scheduled for anti-TB
therapy initiation and individuals coming from contact tracing studies. Patient groups were
defined based on the following criteria: (i) active pulmonary TB patients with microbiologic
confirmation by culture, a compatible radiography with the disease and good clinical response
to anti-TB chemotherapy. (ii) Asymptomatic individuals coming from contact tracing studies
where the index case was smear and culture positives. LTBI was defined in this population as
having positive IGRAs (T-SPOT.TB and/or QFN-G-IT) and a chest radiography without alter-
ations. Exclusion criteria were having a previous known contact, a prior documented positive
TST and an anti-TB therapy prescription in the past. All patients included in the present study
were tested with both IGRAs (QFN-G-IT and T-SPOT.TB).
Technical procedures
TST was performed according the Mantoux technique using two tuberculin units of PPD
RT23 (Statens Serum Institut, Copenhagen, Denmark), and was evaluated within 48-72h by
trained nurses and doctors. All TST5mm were classified as a positive result independently of
the BCG status according to the Spanish Pneumology and Thoracic Surgery Society guidelines
[19]. T-SPOT.TB and QFN-G-IT were processed and interpreted according manufacturer’s
instructions provided in the kits.
Tobacco impact on tuberculosis
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Study variables
Clinical (symptoms and pathology), radiological and microbiological (smear and culture) data
was recorded. Presence of comorbidities was analyzed for diabetes, HIV co-infection and
chronic obstructive pulmonary disease (COPD). Other pathologies as end-stage renal disease,
pancreatitis, psychological disorders and hepatitis were grouped together as “comorbidities”.
Tobacco consumption was investigated by means of two independent interviews. Smoking
quantity was classified as a standard “pack-years ratio” defined as: (number of cigarettes con-
sumed per day/20) × (number of years the person has smoked) [20]. “Underweight” was con-
sidered when the variable Body Mass Index (BMI) was18.5 [21]. The Social Class variable
was categorized according to the Spanish Occupational National Center (CNO) [22].
Statistical analysis
Qualitative variables are based on the calculation of the number and its percentage. Quantita-
tive variables are based on the calculation of the median and the Interquartile Range (IQR).
The chi-square test and Fisher’s exact test have been used to compare qualitative variables. The
Odds Ratios (OR) and its 95% confidence intervals (CI) were calculated for the associated risk
between variables; the associated variables with a value p<0.05 were analyzed at a multivariate
level by means of a logistic regression and an estimation of an Adjusted Odds Ratio (aOR).
Non-parametric tests (Mann-Whitney, Kolmogorov-Smirnov, Kruskal-Wallis) have been used
to compare quantitative variables according to the categories of the group variable. Sensitivity,
specificity, likelihood ratios (LR), positive and negative predictive values (PPV and NPV), pre-
test and post-test probability of developing active TB were calculated. Data was analyzed with
Epi Info 7.1.2 (www.cdc.gov/epiinfo/7). The overall RD1 response in T-SPOT.TB was calcu-
lated as the sum of the spot forming cells (SFCs) obtained in ESAT-6 and CFP-10 panels.
Results
Patient characteristics
A total of 525 participants were studied: (i) 175 active pulmonary TB patients and (ii) 350 indi-
viduals coming from contact tracing studies, 41 of whom were secondary TB cases (a total of
309 contacts without active TB). Globally, 62.1% (326/525) were men. Mean age (years) ± stan-
dard deviation (SD) was 34.00 ± 13.2. The proportion of tobacco smokers was significantly
higher in TB patients (59.3%; 128/216) with respect to contacts (43%; 133/309; p<0.001). Daily
alcohol consumption frequency was not significant between groups; however, consumption
of>40g/day was higher in active TB patients (25.9%; 56/216) than in contacts (0.6%; 2/309).
Moreover, frequency of social class IV-VI, intravenous drug use (IVDU) and comorbidities
such as diabetes, COPD or HIV co-infection were also higher in TB diseased patients versus
contacts (Tables 1 and 2).
IGRAs performance on active TB patients
Table 1 indicates the main demographic and risk factors according to TST and IGRAs results
in active TB patients. Frequency of positive QFN-G-IT results were lower than that obtained
for T-SPOT.TB (73.1% [158/216] by QFN-G-IT versus 85.2% [184/216] by T-SPOT.TB;
p<0.005). Globally, active TB patients presented seven indeterminate results by any of both
IGRAs; five of them corresponded to smokers. A total 119 active TB patients lost weight as a
diseased symptom. In addition, the 17.2% (37/216) of these diseased patients presented a BMI
18.5. However, BMI variable had no significant differences on IGRAs’ positivity.
Tobacco impact on tuberculosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0182998 August 24, 2017 4 / 17
Table 1. Main demographic characteristics and risk factors according to TST and IGRAs results in TB diseased patients.
Variables N (%) TST5mm QFN-G-IT Positive T-SPOT.TB Positive
N (%) p-value N (%) p-value N (%) p-value
Total 216 (100) 197 (91.2) 158 (73.1) 184 (85.2)
Sex
Male 163 (75.5) 149 (91.4) NS 120 (73.6) NS 143 (87.7) NS
Female 53 (24.5) 48 (90.6) 38 (71.1) 41 (77.4)
BCG
Yes 158 (73.1) 149 (94.3) <0.05 125 (79.1) <0.01 139 (88.0) NS
No 58 (26.9) 48 (82.8) 33 (56.9) 45 (77.6)
SC IV-VI
Yes 174 (80.6) 159 (91.4) NS 130 (74.7) NS 146 (83.9) NS
No 42 (19.4) 38 (90.5) 28 (66.7) 38 (90.5)
Employed
Yes 172 (79.6) 159 (92.4) NS 134 (77.9) <0.005 149 (86.6) NS
No 44 (20.4) 38 (86.4) 24 (54.5) 35 (79.5)
Diagnostic delay
<50 days 129 (59.7) 116 (89.9) NS 99 (76.7) NS 111 (86.0) NS
50 days 87 (40.3) 81 (93.1) 59 (67.8) 73 (83.9)
Immigrant
Yes 145 (67.1) 140 (96.6) <0.001 120 (82.8) <0.001 133 (91.7) <0.01
No 71 (32.9) 57 (80.3) 38 (53.5) 51 (71.8)
Underweight
Yes 37 (17.2) 32 (86.5) NS 23 (62.2) NS 28 (75.7) NS
No 178 (82.8) 164 (92.1) 134 (75.3) 155 (87.1)
Alcohol >40g/day
Yes 56 (25.9) 46 (82.1) <0.01 34 (60.7) <0.05 41 (73.2) <0.01
No 160 (74.1) 151 (94.4) 124 (77.5) 143 (89.4)
IVDU
Yes 22 (10.2) 14 (63.6) <0.005 9 (40.9) <0.001 13 (59.1) <0.005
No 194 (89.8) 183 (94.3) 149 (76.8) 171 (88.1)
Smoking
Yes 128 (59.3) 115 (89.8) NS 84 (65.6) <0.001 103 (80.5) <0.05
No 88 (40.7) 82 (93.2) 74 (84.1) 81 (92.0)
Other co-morbidities
Yes 90 (41.7) 72 (80.0) <0.0001 51 (56.7) <0.001 64 (71.1) <0.001
No 126 (58.3) 125 (99.2) 107 (84.9) 120 (95.2)
Diabetes
Yes 12 (5.6) 11 (91.7) NS 9 (75.0) NS 11 (91.7) NS
No 204 (94.4) 186 (91.2) 149 (73.0) 173 (84.8)
COPD
Yes 27 (12.5) 24 (88.9) NS 11 (40.7) <0.001 18 (66.7) <0.05
No 189 (87.5) 173 (91.5) 147 (77.8) 166 (87.8)
HIV
Yes 13 (6.0) 2 (15.4) <0.0001 2 (15.4) <0.001 5 (38.5) <0.001
No 203 (94.0) 195 (96.1) 156 (76.8) 179 (88.2)
TB: tuberculosis; NS: non-significant; TST: tuberculin skin test; SC: social class; IVDU: intravenous drug users; COPD: chronic obstructive pulmonary
disease; HIV: human immunodeficiency virus
https://doi.org/10.1371/journal.pone.0182998.t001
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Table 2. Main demographic characteristics and risk factors associated with TST and IGRAs positivity in individuals coming from contact tracing
studies (including secondary TB cases).
Variables N (%) TST 5mm QFN-G-IT Positive T-SPOT.TB Positive
N (%) p-value N (%) p-value N (%) p-value
Total 350 (100) 245 (70.0) 131 (37.4) 155 (44.3)
Sex
Male 190 (54.3) 137 (72.1) NS 78 (41.1) NS 92 (48.4) NS
Female 160 (45.7) 108 (67.5) 53 (33.1) 63 (39.4)
BCG
Yes 258 (73.7) 195 (75.6) <0.0005 101 (39.1) NS 114 (44.2) NS
No 92 (26.3) 50 (54.3) 30 (32.6) 41 (44.6)
SC IV-VI
Yes 160 (45.7) 117 (73.1) NS 74 (46.3) <0.005 88 (55.0) <0.0005
No 190 (54.3) 128 (67.4) 57 (30.0) 67 (35.3)
Immigrant
Yes 220 (62.9) 160 (72.7) NS 89 (40.5) NS 103 (46.8) NS
No 130 (37.1) 85 (65.4) 42 (32.3) 52 (40.0)
Alcohol Dailya
Yes 146 (41.8) 112 (76.7) <0.05 74 (50.7) <0.00005 85 (58.2) <0.00005
No 203 (58.2) 133 (65.5) 57 (27.9) 70 (34.3)
IDVU
Yes 3 (0.9) 3 (100.0) NS 1 (33.3) NS 2 (66.7) NS
No 349 (99.1) 242 (69.9) 131 (37.7) 154 (44.4)
Smoking
Yes 162 (46.3) 138 (85.2) <0.0001 97 (59.9) <0.0001 116 (71.6) <0.0001
No 188 (53.7) 107 (56.9) 34 (18.1) 39 (20.7)
Other Comorbidities
Yes 34 (9.7) 31 (91.2) <0.01 19 (55.9) <0.05 21 (61.8) <0.05
No 316 (90.3) 214 (67.7) 112 (35.4) 134 (42.4)
Diabetes
Yes 0 (0.0) 0 (0.0) — 0 (0.0) — 0 (0.0) —
No 350 (100.0) 245 (70.0) 131 (37.4) 155 (44.3)
COPD
Yes 3 (0.9) 3 (100.0) NS 2 (66.7) NS 3 (100.0) NS
No 347 (99.1) 242 (69.9) 129 (37.2) 152 (40.9)
HIV
Yes 3 (0.9) 3 (100.0) NS 2 (66.7) NS 1 (33.3) NS
No 347 (99.1) 242 (69.7) 129 (37.2) 154 (44.4)
IC Smoker
Yes 228 (65.1) 167 (73.2) NS 101 (44.3) <0.0005 119 (52.2) <0.0001
No 122 (34.9) 78 (63.9) 30 (24.6) 36 (29.5)
Living together with IC
Yes 126 (36.0) 89 (70.6) NS 64 (50.8) <0.0005 77 (61.1) <0.00005
No 224 (64.0) 156 (69.6) 67 (29.9) 78 (34.8)
Exposed <50 days
Yes 303 (86.6) 207 (68.3) NS 103 (34.0) <0.005 121 (39.9) <0.0001
No 47 (13.4) 38 (80.9) 28 (59.6) 34 (72.3)
a Two of the contacts (0.6%) consumed >40g/day of alcohol
IC: index case; NS: non-significant; TB: tuberculosis; TST: tuberculin skin test; SC: social class; IVDU: intravenous drug users; COPD: chronic obstructive
pulmonary disease; HIV: human immunodeficiency virus
https://doi.org/10.1371/journal.pone.0182998.t002
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Because of the sensitivity of IGRAs in active TB patients is not 100%, the frequency of false-
negative results in this group was analyzed based on tobacco smoking. T-SPOT.TB and
QFN-G-IT presented 19.5% (25/128) and 34.4% (44/128) of false-negative results respectively
among the smoker group, while only 7.95% (7/88) and 15.9% (14/88) of false-negative results
were observed in non-smokers, respectively. By means of an unconditional logistic regression,
the main factors associated with a false-negative results were: smoking (aOR: 3.35; 95%
CI:1.47–7.61; p<0.05); comorbidities (aOR:32.55; 95%CI:1.18–5.52; p<0.05), diagnostic
delay < 50 days (aOR: 0.40; 95%C.I:0.20–0.79; p<0.005) and immunosuppression (aOR:13.36;
95%CI:1.34–132.52; p<0.05).
Radiological manifestations and microbiological evolution of active TB
patients
Table 3 shows the associations between different TB risk factors and clinical characteristics of
the disease. Smoking patients with active TB presented a high probability of having cavitary
lesions (aOR: 1.88; 95%C.I:1.02–3.46; p<0.005). There were not significant differences
between smokers and non-smokers with respect to the sputum smear result (variable “smear-
positive”). The mean culture negativization (months) ± SD was significantly later in smokers
than in non-smokers (2.47±1.3 versus 1.69±1.4; excluding 16 cases with drug-resistances);
furthermore, days of culture negativization significantly increased when cigarette dose aug-
mented (p<0.001). Based on this fact the need of extending anti-TB chemotherapy in smokers
over non-smokers was required (OR: 3.1; 95%CI:1.13–8.48; p<0.05). In addition, alcohol con-
sumption >40g/day was observed as a risk factor for being smear-positive (aOR: 4.96; 95%
CI:1.99–12.33); p<0.001) and having bilateral lesions (aOR for unilateral lesions: 0.37; 95%
CI:0.16–0.83; p<0.05). Underweight was a risk factor significantly associated with culture pos-
itivity delay (aOR for culture negativization: 0.47; 95%CI:0.19–1.10; p<0.05) and bilateral
lesions (aOR for unilateral lesions: 0.41; 95%CI:0.18–0.94; p<0.05).
Likelihood ratios and predictive values for active TB diagnosis
Both LRs and PVs were calculated in order to estimate the active TB diagnostic accuracy of
TST, QFN-G-IT and T-SPOT.TB. As shown in Table 4, positive LRs observed in smoking
patients were 1.09, 1.16 and 1.18 by TST, QFN-G-IT and T-SPOT.TB respectively. In contrast,
positives LR values obtained in non-smoking patients were 1.73, 6.43 and 6 by TST, QFN-G-IT
and T-SPOT.TB respectively. Similarly, PPVs for IGRAs were higher in non-smokers than in
smokers (QFN-G-IT: PPV in smokers 35.2% versus PPV in non-smokers 98.1%; T-SPOT.TB:
PPV in smokers 50.8% versus PPV in non-smokers 98.9%). In addition, negative LRs and NPV
for IGRAs were higher in smokers than in non-smokers. Negative LRs for QFN-G-IT and
T-SPOT.TB in smokers were 4.38 and 6.88 times as high as in non-smokers (QFN-G-IT: nega-
tive LR in smokers 0.79 versus negative LR in non-smokers 0.18; T-SPOT.TB: negative LR in
smokers 0.62 versus negative LR in non-smokers 0.09).
IGRAs performance in TB contact individuals
Table 2 indicates the possible risk factors associated with TST and IGRAs positivity in individ-
uals coming from contact tracing studies (including the secondary TB cases). A total of 350
individuals were recruited during contact tracing studies, of whom LTBI was diagnosed in a
39.2% (121/309) by QFN-G-IT and/or T-SPOT.TB. In addition, secondary active TB were
found in 11.7% (41/350) of the cases. No indeterminate results were obtained in the group of
contacts. As expected, positive results obtained by TST were significantly higher in BCG indi-
viduals coming from contact tracing studies with respect to non-BCG contacts (p<0.0005),
Tobacco impact on tuberculosis
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Table 3. Associations between different TB risk factors and clinical characteristics of the disease. A multivariate analysis and an aOR has been per-
formed considering statistically significant variables observed in the bivariate analysis.
Variables Cavitary Smear-positive Unilateral Culture negativization (2nd
month)
N (%) aOR (95%
CI)
p-
value
N (%) aOR (95%
CI)
p-value N (%) aOR (95%
CI)
p-
value
N (%) aOR (95%
CI)
p-
value
Sex
Female 19
(35.8)
1 NS 32
(60.4)
NA - - 39
(73.6)
NA -- 41
(77.3)
NA --
Male 85
(52.2)
1.39 (0.80–
3.20)
107
(65.6)
111
(68.1)
116
(71.2)
Diagnostic delay
50 days 49
(56.3)
1 NS 67
(77.0)
1 <0.005 57
(65.5)
NA -- 57
(65.5)
1 NS
<50 days 54
(42.5)
0.60 (0.34–
1.06)
71
(55.9)
0.35 (0.19–
0.66)
92
(72.4)
99
(79.8)
1.90(0.95–
3.78)
Alcohol >40g/day
No 69
(43.1)
1 NS 90
(56.3)
1 <0.001 125
(78.1)
1 <0.05 124
(79.0)
1 NS
Yes 35
(62.5)
1.58 (0.78–
3.22)
49
(87.5)
4.96 (1.99–
12.33)
25
(44.6)
0.37 (0.16–
0.83)
33
(58.9)
0.64 (0.3–
1.36)
Smoking
No 31
(35.2)
1 <0.05 50
(56.8)
NA - - 71
(80.7)
1 NS 76
(86.4)
1 <0.05
Yes 73
(57.0)
1.88 (1.02–
3.46)
89
(69.5)
79
(61.7)
0.63 (0.31–
1.30)
81
(64.8)
0.36 (0.15–
0.82)
IVDU
No 91
(46.9)
NA -- 121
(62.4)
NA - - 139
(71.6)
1 NS 144
(75.4)
NA --
Yes 13
(59.1)
18
(81.8)
11
(50.0)
1.27 (0.43–
3.74)
13
(59.1)
BCG
No 30
(51.7)
NA -- 43
(74.1)
1 NS 33
(56.9)
1 NS 40
(69.0)
NA --
Yes 74
(46.8)
96
(60.8)
1.10 (0.49–
2.48)
117
(74.1)
0.78 (0.24–
2.50)
117
(75.5)
Immigrant
No 37
(52.1)
NA -- 51
(71.8)
NA - - 38
(53.5)
1 NS 48
(67.6)
NA --
Yes 67
(46.2)
88
(60.7)
112
(77.2)
1.83 (0.55–
6.13)
109
(76.8)
Social Class IV-VI
No 21
(50.0)
NA -- 26
(61.9)
NA - - 30
(71.4)
NA -- 30
(75.0)
NA --
Yes 82
(47.4)
112
(64.7)
120
(69.4)
127
(73.8)
HIV positive
No 101
(49.8)
NA -- 131
(64.5)
NA - - 144
(70.9)
NA -- 144
(72.0)
NA --
Yes 3 (23.1) 8 (61.5) 6 (46.2) 13 (100)
Diabetes
(Continued )
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indicating that the vaccine influences TST result. There were no significant differences on the
age (years ± SD) between LTBI and non-LTBI individuals (31.7±12.5 versus 30.3±11.3). The
group of contacts presented 10.3% (36/350) of discordant QFN-G-IT/T-SPOT.TB results (30
cases were QFN-G-IT negative/T-SPOT.TB positive, and six cases were QFN-G-IT positive/
T-SPOT.TB negative). By means of an unconditional logistic regression, being a smoker was
the unique variable (from all variables analyzed in Table 2) related with IGRAs’ discordant
results (aOR: 5.42; 95% CI:1.86–15.79; p<0.005). Furthermore, smoking contacts presented a
significantly higher LTBI prevalence when compared with non-smokers (p<0.0001). After-
wards, LTBI risk factors were studied by bivariate and multivariate analysis (Table 5). Smoking
(aOR: 11.24; 95%CI:5.78–21.85; p<0.00005), having a daily contact of>6h (aOR: 1.90; 95%
CI:1.03–3.49; p<0.05) and being a contact of a smoking index case (aOR: 1.92; 95%CI:1.04–
3.55; p<0.05) were the main risk factors associated with LTBI. Moreover, LTBI, non-LTBI and
secondary active TB cases found during contact tracing studies were stratified regarding smok-
ing or non-smoking condition. Interestingly, the percentage of secondary active TB cases and
LTBI individuals was higher in smokers versus non-smokers (secondary active TB: 18.5% in
smokers vs. 5.9% in non-smokers; LTBI: 56.8% in smokers vs. 15.4% in non-smokers; Fig 1).
Impact of tobacco smoking on M. tuberculosis IFN-γ immune response
The impact of smoking on M. tuberculosis immune response was analyzed as the amount of
IFN-γ secreted (UI/mL) in QFN-G-IT and as the number of T-cells producing IFN-γ (SFCs)
in T-SPOT.TB (Table 6). In active TB patients, the response for both assays was significantly
Table 3. (Continued)
Variables Cavitary Smear-positive Unilateral Culture negativization (2nd
month)
N (%) aOR (95%
CI)
p-
value
N (%) aOR (95%
CI)
p-value N (%) aOR (95%
CI)
p-
value
N (%) aOR (95%
CI)
p-
value
No 98
(48.0)
NA -- 128
(62.7)
1 NS 142
(69.6)
NA -- 152
(75.6)
1 <0.01
Yes 6 (50.0) 11
(91.7)
7.7(0.93–
63.8)
8 (66.7) 5 (41.7) 0.16 (0.04–
0.61)
Other
Comorbidities
No 59
(46.8)
NA -- 75
(59.5)
NA - - 98
(77.8)
1 NS 96
(77.4)
Yes 45
(50.0)
64
(71.1)
52
(57.8)
0.79 (0.35–
1.75)
61
(68.5)
NA
COPD
No 88
(46.6)
NA -- 116
(61.4)
1 NS 137
(72.5)
1 NS 141
(75.8)
NA --
Yes 16
(59.3)
23
(85.2)
1.70 (0.50–
5.81)
13
(48.1)
1.28 (0.44–
3.71)
16
(59.3)
Underweight
No 80
(44.9)
NA -- 110
(61.8)
NA - - 132
(74.2)
1 <0.05 137
(78.3)
1 <0.05
Yes 23
(62.2)
28
(75.7)
17
(45.9)
0.41 (0.18–
0.94)
20
(54.1)
0.47 (0.19–
1.10)
NA: non-applicable. Non-significant variables in the bivariate analysis were non-applicable in the multivariate analysis; TB: tuberculosis; aOR: adjusted
Odds Ratio; CI: confidence interval; NS: non-significant; COPD: chronic obstructive pulmonary disease; IVDU: intravenous drug users; HIV: human
immunodeficiency virus; COPD: chronic obstructive pulmonary disease
https://doi.org/10.1371/journal.pone.0182998.t003
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higher in non-smokers than in smokers. In LTBI individuals there were numerically more pos-
itives in the smoker group based on the diagnosis with IGRAs. However, IFN-γ responses
were higher in non-smokers than in smokers. IFN-γ response was related with the smoking
dose and it was quantified as pack-years. As a result, a dose-dependent relation was observed
between the smoking quantity and the IFN-γ response analyzed by QFN-G-IT and T-SPOT.
TB for active TB patients and LTBI contacts. This immune response significantly decreased
when the pack-years consumption augmented, with the exception of T-SPOT.TB, where the
difference in LTBI individuals is not significant (Table 6).
Discussion
Reducing mortality caused by tobacco-related diseases such as TB continues to be an impor-
tant goal in clinical microbiology and public health. We have assessed in the present study
how tobacco smoke can influence TB radiological manifestations, sputum culture conversion
and the immune response against M. tuberculosis by means of QFN-G-IT and T-SPOT.TB
Table 4. Likelihood ratios, pre- and post-Test probabilities of TST, QFN-G-IT and T-SPOT.TB in smoker and non-smoker patients.
Test TB
cases
Non
TB
cases
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV %
(95%
CI)
NPV %
(95%
CI)
LR
positive
(95% CI)
LR
negative
(95% CI)
Positive Pre-
Test
Probability
Positive
Post-Test
Probability
Negative
Post-Test
Probability
Smoker
TST 5mm 115 110 0.9 0.17 49.01 94.31 1.09 0.59 0.49 0.51 0.36
TST < 5mm 13 23 (0.85–0.95) (0.11–0.24) (0.0–
86.42)
(86.4–
100.0)
(0.99–1.2) (0.31–
1.11)
Non-
smoker
TST 5mm 82 95 0.93 0.46 92.18 91.16 1.73 0.15 0.33 0.46 0.07
TST < 5mm 6 81 (0.88–0.98) (0.39–0.53) (76.8–
99.4)
(86.6–
94.8)
(1.49–2) (0.07–
0.33)
Smoker
QFN.G-IT
pos
84 75 0.66 0.44 35.24 95.62 1.16 0.79 0.49 0.53 0.43
QFN.G-IT
neg
44 58 (0.57–0.74) (0.35–0.52) (0.00–
74.5)
(86.7–
100.0)
(0.96–
1.41)
(0.58–
1.07)
Non-
smoker
QFN.G-IT
pos
74 23 0.84 0.87 98.1 64.9 6.43 0.18 0.33 0.74 0.36
QFN.G-IT
neg
14 153 (0.76–0.92) (0.82–0.92) (94.0–
99.8)
(32.1–
79.2)
(4.35–
9.52)
(0.11–0.3)
Smoker
T-SPOT.TB
pos
103 91 0.80 0.32 50.77 93.62 1.18 0.62 0.49 0.53 1.5
T-SPOT.TB
neg
25 42 (0.74–0.87) (0.24–0.39) (0.00–
82.7)
(85.5–
100.0)
(1.02–
1.16)
(0.4–0.95)
Non-
smoker
T-SPOT.TB
pos
81 27 0.92 0.85 98.95 67.02 6.0 0.09 0.33 0.75 0.05
T-SPOT.TB
neg
7 149 (0.86–0.98) (0.79–0.9) (96.3–
99.9)
(40.2–
79.5)
(4.22–
8.54)
(0.05–
0.19)
Pos: positive; neg: negative; TB: tuberculosis; PPV: positive predictive value; NPV: negative predictive value; LR: likelihood ratio; CI: confidence interval
https://doi.org/10.1371/journal.pone.0182998.t004
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results. The impact of tobacco smoke was examined in active TB patients and individuals com-
ing from contact tracing studies. Our results demonstrate that smoking was associated with
cavitary and bilateral radiological findings, culture positivity delay and IGRAs false-negative
results in active TB patients. Furthermore, smoking was a risk factor for LTBI in contact indi-
viduals. Interestingly, a decreased IFN-γ response was observed in smokers. This response was
dose-dependent, with increasing pack-years associated with decreased IFN-γ response.
IGRAs’ sensitivity is limited during active TB [23–25]; however, the presence of false-nega-
tive results is even higher in patients who smoke most likely due to the altered inflammatory
Table 5. LTBI risk factors analysed by bivariate and multivariate analysis.
Variables LTBIa Bivariate Analysis Multivariate Analysis
N (%) aOR (95% CI) p-value aOR (95% CI) p-value
Total 121 (39.2)
Sex
Female 54 (37.0) 1 NS -- - -
Male 67 (41.1) 1.19 (0.75–1.88)
BCG
No 33 (39.8) 1 NS -- - -
Yes 88 (38.9) 0.96 (0.57–1.63)
SC IV-VI
No 59 (33.1) 1 <0.01 1 NS
Yes 62 (47.3) 1.81 (1.14–2.88) 1.51 (0.84–2.70)
Immigrant
No 43 (36.4) 1 NS -- - -
Yes 78 (40.8) 1.20 (0.75–1.93)
Alcohol Daily
No 49 (27.2) 1 <0.00005 1 NS
Yes 72 (56.3) 3.44 (2.13–5.55) 1.00 (0.51–1.94)
Smoking
No 29 (16.5) 1 <0.00005 1 <0.00005
Yes 92 (69.3) 11.74 (6.59–21.05) 11.57 (5.97–22.41)
Other co-morbidities
No 109 (37.8) 1 NS -- - -
Yes 12 (57.1) 2.19 (0.89–5.36)
HIV (+)
No 119 (38.9) 1 NS -- - -
Yes 2 (66.7) 3.14 (0.28–35.04)
IC Smoker
No 27 (24.1) 1 <0.00005 1 <0.05
Yes 94 (47.7) 2.87 (1.72–4.81) 1.94 (1.05–3.57)
Daily >6 hours
No 64 (34.4) 1 <0.05 1 <0.05
Yes 57 (46.3) 1.64 (1.03–2.62) 1.81 (1.01–3.31)
Exposed <50 days
No 20 (64.5) 1 <0.005 1 NS
Yes 101 (36.3) 0.31 (0.14–0.68) 0.56 (0.21–1.50)
a LTBI was defined in this population as having positive IGRAs (T-SPOT.TB and/or QFN-G-IT) and a chest radiography without alterations.
LTBI: latent tuberculosis infection; aOR: adjusted Odds Ratio; CI: confidence interval; SC: social class; IC: index case; NS: non-significant.
https://doi.org/10.1371/journal.pone.0182998.t005
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response associated with smoking. These findings have been previously shown by Aabye and
colleagues, concluding that tobacco smokers with active TB present an impaired QFN-G-IT
performance associated with false-negative and indeterminate results [26]. Furthermore, LRs
and PVs observed in our study in such population also reinforces these findings. LRs and PVs
indicate that tobacco smoke influences IGRAs’ performance and it is associated with false-
negative results in smokers [27]. Furthermore, others have also described smoking as an inde-
pendent factor involved in the risk of LTBI development [28–30]. Therefore, our results on
smoking patients with active TB and individuals coming from contact tracing studies firmly
support previous findings on QFN-G-IT and illustrate novel ones based on the T-SPOT.TB
assay.
It has been experimentally demonstrated that tobacco smoke inhibits the proliferation of
IFN-γ producing T-cells coming from the lungs of M. tuberculosis infected mice [16]. In line
with this, studies indicate that alveolar compartments from active TB patients are enriched
with a specific T-cell subset (called regulatory T-cells or Tregs) which down-regulates the effec-
tor immune response. Moreover, these Treg cells reduce the capacity of alveolar and/or mono-
cyte-derived macrophages to control M. tuberculosis growth [31]. Interestingly, this regulatory
profile is enhanced in smokers’ macrophages producing less effector cytokines than non-
smokers after infection with M. tuberculosis [32, 33]. Altogether, these findings suggest that T-
cell functions are highly reduced in smokers and that host defense mechanisms in the lung of
individuals exposed to tobacco smoke weakly fight against M. tuberculosis infection. Our work
Fig 1. Final diagnosis of all the individuals recruited during contact tracing studies. LTBI, non-LTBI
and secondary active TB cases were stratified regarding their smoking or non-smoking condition. LTBI was
defined as having positive IGRAs (T-SPOT.TB and/or QFN-G-IT) and a chest radiography without alterations.
Active TB cases presented microbiologic confirmation by culture, a compatible radiography with the disease
and good clinical response to anti-TB chemotherapy.
https://doi.org/10.1371/journal.pone.0182998.g001
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compliments these observations, specifically that smoking alters the immune response
decreasing the number of IFN-γ secreting T-cells in T-SPOT.TB and the amount of this cyto-
kine in QFN-G-IT. Subsequently, smokers have high susceptibility of being LTBI infected if
they are exposed to the bacilli. Furthermore, we cannot also discard the possibility of being
underestimating LTBI diagnosis in smoking contacts due to immune dysfunction. All contacts
with negative and positive IGRAs (who received chemoprophylaxis) within the study were fol-
lowed-up and none of them developed active TB. This data reflects that IGRAs have a high
negative predicting value, which is in accordance with previous findings of our research group
[34]. In this study, being a contact of a smoking index case was another risk factor associated
with LTBI. This could be attributable to more frequent cough in smoking index TB patients,
and as a consequence, a higher transmission of the disease through their close contacts [35].
It is shown here that a negative dose-response relation exits between the amount of ciga-
rettes smoked and the IFN-γ response in active TB patients and LTBI individuals. Therefore,
an increment of tobacco smoking produces a reduction of these responses observed by both
IGRAs. This inverse correlation was also observed in a previous study using QFN-G-IT in
HIV-infected individuals for LTBI detection [36]. The alteration on IFN-γ producing T-cells
and/or the secreted levels of this cytokine persists as long as the individual continues smoking.
As a consequence, several factors such as re-infections, immune risk adjuvants and self-M.
tuberculosis strain pathogenicity could contribute in triggering TB disease [37]. Indeed, 71.1%
(91/128) within our cohort of smokers with active TB, smoked more than 15 pack-years versus
18.3% (17/93) of LTBI smokers and 5% (2/40) of non-LTBI smokers. Additionally, pack-years
estimation not only depends on cigarette numbers, but also on years the individual has been
smoking. Therefore, number of smoking years exacerbates the negative effect of tobacco
Table 6. Impact of tobacco smoking on Mycobacterium tuberculosis immune response.
N (%) QFN-G-IT (IU/ml) T-SPOT.TB (SFC)
Median (IQR) p-Value Median (IQR) p-Value
Active TB
Total 216 (100) 2.15 (0.30–6.27) 58.50 (16.00–111.00)
Smoking
Yes 128 (59.3) 0.93 (0.20–3.35) <0.0001 38.5 (13.00–99.00) <0.0005
No 88 (40.7) 3.37 (1.44–9.54) 75.5 (30.00–134.00)
Pack-years
None 88 (40.7) 3.37 (1.44–9.54) <0.0005 75.5 (30.00–134,00) <0.01
1–5 16 (7.4) 2.54 (0.64–5.65) 59.0 (12.00–101.00)
6–15 21 (9.7) 1.71 (0.25–3.22) 47.00 (16.50–105.00)
>15 91 (42.1) 0.87 (0.13–3.02) 38.50 (13.00–83.00)
LTBI contacts
Total 121 (100) 1.61 (0.65–5.34) 33.00 (18.00–66.00)
Smoking
Yes 93 (76.9) 1.29 (0.48–4.03) <0.05 31.00 (17.00–53.00) <0.05
No 28 (23.1) 4.65 (0.78–10.58) 50.00 (25.00–144.00)
Pack-years
None 28 (23.1) 4.65 (0.78–10.58) <0.05 50.00 (25.00–144.00) NS
1–5 41 (33.9) 2.10 (0.65–4.78) 38.00 (20.00–57.00)
6–15 35 (28.9) 1.24 (0.35–4.02) 24.00 (15.00–46.00)
>15 17 (14.1) 0.94 (0.83–1.16) 24.00 (15.00–50.00)
SFC: spot-forming cells; IQR: interquartile range; TB: tuberculosis; LTBI: latent tuberculosis infection.
https://doi.org/10.1371/journal.pone.0182998.t006
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smoke. In our study, mean age (years) ± SD of active TB patients who smoked >15 pack-years
versus those who smoked <15 pack-years was 45.02 ± 11.15 and 33.83±13.7, respectively.
The same tendency was observed in LTBI individuals, mean ages (years) ± SD in those who
smoked >15 pack-years or<15 pack-years were 40.00±8.1 and 30.00±12.55, respectively.
The impact of smoke cessation on immunity against M. tuberculosis is controversial. It has
been shown in a murine model that tobacco smoke cessation is beneficial to pulmonary TB
control and allows a quick recovery of anti-mycobacterial immunity [18]. In contrast, O’Leary
et al. observed that an impaired immune response to M. tuberculosis is maintained in alveolar
macrophages from ex-smokers [32]. As found in this study and others [10, 38, 39], smoking
affects clinical TB manifestations by increasing cavitary and bilateral radiological findings. The
impaired immune response observed in smokers due to decreased IFN-γ cytokine secretion
may result in increased susceptibility to sever forms of the disease. In addition, a delay of cul-
ture negativization is observed in smokers, this finding is also dose-dependent related and
results in prolonged treatment, with increased costs associated with therapy and surveillance.
[6, 9, 40, 41].
Besides the important findings obtained here, some limitations need to be addressed. First,
a single IFN-γ blood quantification may not be sufficient to characterize the alteration of the
immune response as a consequence of direct tobacco smoking. Therefore, it may be encourag-
ing to detect and monitor several cytokines and cell populations in blood and bronchoalveolar
lavage of individuals with an impaired immune system such as smokers. Second, the number
of patients who stopped smoking included in this study is limited and may not be adequate
to assess how smoke cessation would influence the immune response against M. tuberculosis
(6 out of the 128 active TB patients who smoked stopped). However, results illustrated here
strengthen the observation that quantity and length of tobacco smoking negatively impairs the
immune system.
In conclusion, we here describe that (i) patients with active TB who smoke have a negative
effect on radiological manifestations, sputum culture conversions in a dose-dependent man-
ner, and treatment extension, (ii) tobacco smoke increases probability of false-negative IGRA
results in active TB and LTBI patients due to decreased IFN-γ secretion, and (iii) IFN-γ
response is affected by smoking being related with the pack-years consumption. Thus, this
study adds further data about clinical performance according to tobacco smoke, which could
help to explain and understand false-negative and indeterminate QFN-G-IT and T-SPOT.TB
assays results on smokers. Furthermore, our data establish an association between tobacco
and TB outcome due to a weaken host immune response caused by tobacco smoke. Advising
smoke cessation and avoiding smoke exposure are two important measures for TB control
[3, 42, 43]. Efforts to integrate smoking cessation interventions into TB directly DOT short-
course have been performed improving the outcome of active TB patients [44, 45]. However,
in spite of the efforts carried out in our study setting, only a low number of smoking patients
with active TB quit tobacco smoking. Altogether making efforts on smoking cessation could
improve quality life on TB patients and their clinical outcome of the disease.
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